Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study
Background: Sodium selenite at high dose exerts antitumor effects and increases efficacy of cytostatic drugs in multiple preclinical malignancy models. We assessed the safety and efficacy of intravenous administered sodium selenite in cancer patients’ refractory to cytostatic drugs in a phase I tria...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-06-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6643/7/6/4978 |
id |
doaj-482880ddef194395926f64e09a199b25 |
---|---|
record_format |
Article |
spelling |
doaj-482880ddef194395926f64e09a199b252020-11-24T22:21:23ZengMDPI AGNutrients2072-66432015-06-01764978499410.3390/nu7064978nu7064978Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR StudyOla Brodin0Staffan Eksborg1Marita Wallenberg2Charlotte Asker-Hagelberg3Erik H. Larsen4Dag Mohlkert5Clara Lenneby-Helleday6Hans Jacobsson7Stig Linder8Sougat Misra9Mikael Björnstedt10Department of Oncology, Karolinska Institutet, Karolinska University Hospital Södersjukhuset, SE-118 83 Stockholm, SwedenDepartment of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital Solna, SE-171 76 Stockholm, SwedenDepartment of Laboratory Medicine, Division of Pathology F46, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, SwedenMedical Products Agency, P.O. Box 26, SE-751 03 Uppsala, SwedenNational Food Institute, Technical University of Denmark, DK-2860 Søborg, DenmarkDepartment of Radiology, Karolinska University Hospital Södersjukhuset, SE-171 76 Stockholm, SwedenDepartment of Oncology, Karolinska Institutet, Karolinska University Hospital Södersjukhuset, SE-118 83 Stockholm, SwedenDepartment of Radiology, Karolinska University Hospital, Solna, SE-171 76 Stockholm, SwedenDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm SE-171 76, SwedenDepartment of Laboratory Medicine, Division of Pathology F46, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, SwedenDepartment of Laboratory Medicine, Division of Pathology F46, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, SwedenBackground: Sodium selenite at high dose exerts antitumor effects and increases efficacy of cytostatic drugs in multiple preclinical malignancy models. We assessed the safety and efficacy of intravenous administered sodium selenite in cancer patients’ refractory to cytostatic drugs in a phase I trial. Patients received first line of chemotherapy following selenite treatment to investigate altered sensitivity to these drugs and preliminary assessment of any clinical benefits. Materials and Methods: Thirty-four patients with different therapy resistant tumors received iv sodium selenite daily for consecutive five days either for two weeks or four weeks. Each cohort consisted of at least three patients who received the same daily dose of selenite throughout the whole treatment. If 0/3 patients had dose-limiting toxicities (DLTs), the study proceeded to the next dose-level. If 2/3 had DLT, the dose was considered too high and if 1/3 had DLT, three more patients were included. Dose-escalation continued until the maximum tolerated dose (MTD) was reached. MTD was defined as the highest dose-level on which 0/3 or 1/6 patients experienced DLT. The primary endpoint was safety, dose-limiting toxic effects and the MTD of sodium selenite. The secondary endpoint was primary response evaluation. Results and Conclusion: MTD was defined as 10.2 mg/m2, with a calculated median plasma half-life of 18.25 h. The maximum plasma concentration of selenium from a single dose of selenite increased in a nonlinear pattern. The most common adverse events were fatigue, nausea, and cramps in fingers and legs. DLTs were acute, of short duration and reversible. Biomarkers for organ functions indicated no major systemic toxicity. In conclusion, sodium selenite is safe and tolerable when administered up to 10.2 mg/m2 under current protocol. Further development of the study is underway to determine if prolonged infusions might be a more effective treatment strategy.http://www.mdpi.com/2072-6643/7/6/4978sodium selenitecarcinomapharmacokineticsmaximum tolerated dose |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ola Brodin Staffan Eksborg Marita Wallenberg Charlotte Asker-Hagelberg Erik H. Larsen Dag Mohlkert Clara Lenneby-Helleday Hans Jacobsson Stig Linder Sougat Misra Mikael Björnstedt |
spellingShingle |
Ola Brodin Staffan Eksborg Marita Wallenberg Charlotte Asker-Hagelberg Erik H. Larsen Dag Mohlkert Clara Lenneby-Helleday Hans Jacobsson Stig Linder Sougat Misra Mikael Björnstedt Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study Nutrients sodium selenite carcinoma pharmacokinetics maximum tolerated dose |
author_facet |
Ola Brodin Staffan Eksborg Marita Wallenberg Charlotte Asker-Hagelberg Erik H. Larsen Dag Mohlkert Clara Lenneby-Helleday Hans Jacobsson Stig Linder Sougat Misra Mikael Björnstedt |
author_sort |
Ola Brodin |
title |
Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study |
title_short |
Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study |
title_full |
Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study |
title_fullStr |
Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study |
title_full_unstemmed |
Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study |
title_sort |
pharmacokinetics and toxicity of sodium selenite in the treatment of patients with carcinoma in a phase i clinical trial: the secar study |
publisher |
MDPI AG |
series |
Nutrients |
issn |
2072-6643 |
publishDate |
2015-06-01 |
description |
Background: Sodium selenite at high dose exerts antitumor effects and increases efficacy of cytostatic drugs in multiple preclinical malignancy models. We assessed the safety and efficacy of intravenous administered sodium selenite in cancer patients’ refractory to cytostatic drugs in a phase I trial. Patients received first line of chemotherapy following selenite treatment to investigate altered sensitivity to these drugs and preliminary assessment of any clinical benefits. Materials and Methods: Thirty-four patients with different therapy resistant tumors received iv sodium selenite daily for consecutive five days either for two weeks or four weeks. Each cohort consisted of at least three patients who received the same daily dose of selenite throughout the whole treatment. If 0/3 patients had dose-limiting toxicities (DLTs), the study proceeded to the next dose-level. If 2/3 had DLT, the dose was considered too high and if 1/3 had DLT, three more patients were included. Dose-escalation continued until the maximum tolerated dose (MTD) was reached. MTD was defined as the highest dose-level on which 0/3 or 1/6 patients experienced DLT. The primary endpoint was safety, dose-limiting toxic effects and the MTD of sodium selenite. The secondary endpoint was primary response evaluation. Results and Conclusion: MTD was defined as 10.2 mg/m2, with a calculated median plasma half-life of 18.25 h. The maximum plasma concentration of selenium from a single dose of selenite increased in a nonlinear pattern. The most common adverse events were fatigue, nausea, and cramps in fingers and legs. DLTs were acute, of short duration and reversible. Biomarkers for organ functions indicated no major systemic toxicity. In conclusion, sodium selenite is safe and tolerable when administered up to 10.2 mg/m2 under current protocol. Further development of the study is underway to determine if prolonged infusions might be a more effective treatment strategy. |
topic |
sodium selenite carcinoma pharmacokinetics maximum tolerated dose |
url |
http://www.mdpi.com/2072-6643/7/6/4978 |
work_keys_str_mv |
AT olabrodin pharmacokineticsandtoxicityofsodiumseleniteinthetreatmentofpatientswithcarcinomainaphaseiclinicaltrialthesecarstudy AT staffaneksborg pharmacokineticsandtoxicityofsodiumseleniteinthetreatmentofpatientswithcarcinomainaphaseiclinicaltrialthesecarstudy AT maritawallenberg pharmacokineticsandtoxicityofsodiumseleniteinthetreatmentofpatientswithcarcinomainaphaseiclinicaltrialthesecarstudy AT charlotteaskerhagelberg pharmacokineticsandtoxicityofsodiumseleniteinthetreatmentofpatientswithcarcinomainaphaseiclinicaltrialthesecarstudy AT erikhlarsen pharmacokineticsandtoxicityofsodiumseleniteinthetreatmentofpatientswithcarcinomainaphaseiclinicaltrialthesecarstudy AT dagmohlkert pharmacokineticsandtoxicityofsodiumseleniteinthetreatmentofpatientswithcarcinomainaphaseiclinicaltrialthesecarstudy AT claralennebyhelleday pharmacokineticsandtoxicityofsodiumseleniteinthetreatmentofpatientswithcarcinomainaphaseiclinicaltrialthesecarstudy AT hansjacobsson pharmacokineticsandtoxicityofsodiumseleniteinthetreatmentofpatientswithcarcinomainaphaseiclinicaltrialthesecarstudy AT stiglinder pharmacokineticsandtoxicityofsodiumseleniteinthetreatmentofpatientswithcarcinomainaphaseiclinicaltrialthesecarstudy AT sougatmisra pharmacokineticsandtoxicityofsodiumseleniteinthetreatmentofpatientswithcarcinomainaphaseiclinicaltrialthesecarstudy AT mikaelbjornstedt pharmacokineticsandtoxicityofsodiumseleniteinthetreatmentofpatientswithcarcinomainaphaseiclinicaltrialthesecarstudy |
_version_ |
1725771422172708864 |